Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | TTBK1 | Q5TCY1 | 8/20 | 0.50 |
| ▸ | TTBK2 | Q6IQ55 | 8/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19082950 | 0.80 | TSHR (0.39) | HDAC6 | |
| SCHEMBL17017326 | 0.79 | CYP1A2 (0.59) | TTBK1PTK2MKNK1HPGDS | |
| SCHEMBL17017339 | 0.76 | RECQL (0.36) | — | |
| SCHEMBL4354437 | 0.74 | JAK2 (0.68) | HDAC6TTBK1TTBK2BTK | |
| SCHEMBL24804993 | 0.72 | HDAC6 (0.66) | HDAC6TTBK1TTBK2PTK2 | |
| SCHEMBL22346237 | 0.72 | HDAC6 (0.62) | HDAC6TTBK1TTBK2PTK2HPGDS | |
| SCHEMBL28762132 | 0.72 | TTBK1 (0.56) | HDAC6TTBK1TTBK2MKNK1MKNK2 | |
| SCHEMBL20119913 | 0.72 | POLB (0.66) | HDAC6 | |
| SCHEMBL191323 | 0.72 | HDAC6 (0.46) | HDAC6TTBK1TTBK2PTK2MKNK1 | |
| SCHEMBL28103460 | 0.72 | TTBK1 (0.52) | HDAC6TTBK1TTBK2PTK2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | HDAC6 577/4885TTBK1 635/4885TTBK2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.